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Sputum Proteomics in Inflammatory and Suppurative
Respiratory Diseases
Robert D. Gray1, Gordon MacGregor1, Donald Noble1, Margaret Imrie1, Maria Dewar1, A. Christopher Boyd1,
J. Alastair Innes1, David J. Porteous1, and Andrew P. Greening1
1School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
Rationale: Markers of inflammatory activity are important for assess-
mentandmanagementofmanyrespiratorydiseases.Markers thatare
currently unrecognized may be more valuable than those presently
believed to be useful.
Objectives: To identify potential biomarkers of suppurative and in-
flammatory lung disease in induced sputum samples.
Methods: Induced sputum was collected from 20 healthy control
subjects, 24 patients with asthma, 24with chronic obstructive pulmo-
nary disease, 28 with cystic fibrosis (CF), and 19 with bronchiectasis.
Twelve patients with CF had sputum sampled before and after
antibiotic therapy for an infective exacerbation. The fluid phase of
induced sputumwas analyzed by surface-enhanced laser desorption/
ionization time-of-flight (SELDI-TOF) mass spectroscopy on three
protein array surfaces. Some protein markers were selected for
identification, and relevant ELISA assays sought. For 12 patients with
CF, both SELDI-TOF and ELISA monitored changes in inflammatory
responses during infective exacerbations.
Measurements and Main Results: SELDI-TOF identified potential bio-
markers that differentiated each of the disease groups from healthy
control subjects: at a significance of P , 0.01, there were 105 for
asthma, 113 for chronic obstructive pulmonary disease, 381 for CF,
and 377 for bronchiectasis. Peaks selected for protein identification
yielded calgranulin A, calgranulin B, calgranulin C, Clara cell secretory
protein, lysosyme c, proline rich salivary peptide, cystatin s, and
hemoglobin a. On treatment of an infective CF exacerbation, SELDI-
TOF determined falls in levels of calgranulin A and calgranulin B that
weremirroredbyELISA-measuredfalls incalprotectin (heterodimerof
calgranulins A and B).
Conclusions: Proteomic screening of sputum yields potential bio-
markers of inflammation. The early development of a clinically rele-
vant assay from such data is demonstrated.
Keywords: biomarkers; calprotectin; cystic fibrosis
Although there is considerable clinical and research need for
good assessment of inflammation in airway diseases, the re-
quirement of relatively invasive procedures, such as bronchos-
copy and bronchoalveolar lavage (BAL), precludes sampling
from a wide range of patients and on repeated occasions. This
has encouraged investigators to use techniques of exhaled gases
and exhaled breath condensate (EBC) analysis, although there
may be limitations of value (1–10). The cellular phase of
induced sputum is helpful in evaluating and monitoring asthma
(11), but its use in suppurative lung diseases such as cystic
fibrosis (CF) is less clear, although in children induced sputum
measurements have been shown to correlate with lung function
(12). The fluid phase of sputum has been rather underutilized;
however, potential problems of variability in noncellular mate-
rial may be encountered and as yet there is no agreed-upon
correction factor as in BAL sampling.
Surface-enhanced laser desorption/ionization time-of-flight
(SELDI-TOF) technology has been used to discover bio-
markers of disease groups in direct comparison to control
groups. The primary focus of much of this research has been
to determine diagnostic biomarkers in a wide range of diseases,
such as rheumatoid arthritis, HIV infection (13), prostate cancer
(14), ovarian cancer (15, 16), motor neurone disease (17),
ischemic heart disease (18), and infectious diseases (19, 20),
using a diverse range of body fluids, such as serum, urine,
cerebrospinal fluid, and joint fluid. The generated protein
profiles demonstrate differences between disease groups and
individual proteins may be identified to act as biomarkers either
alone or in tandem with others. SELDI-TOF data may be used
to generate serum ‘‘protein fingerprints’’ using bioinformatics to
provide a potential diagnostic test in cancer and infectious
diseases (15, 19, 20). This approach relies on interpretation of
mass spectral patterns rather than identifying individual pro-
teins and has been widely criticized in the literature and, in
some cases, such as the work of Petricoin and colleagues (15),
analysis of data sets independently have led to completely
different conclusions (21). Baggerly and coworkers (21) dem-
onstrated that inconsistent data processing can alter the ulti-
mate outcome of these sorts of experiments. A different, and
more direct, approach is to identify the actual proteins re-
sponsible for the mass spectral peaks provided by mass spec-
trometry (MS) data. Indeed, the identification of key bio-
markers after initial proteomic studies may provide a more
viable route to clinical application (22) and furthermore may
allow the functional importance of such markers to be in-
vestigated. Therefore, using SELDI-TOF as a screening tool
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Induced sputum cytology has been used to investigate
a number of respiratory diseases, including asthma. The
fluid phase is less well characterized and likely to contain
undiscovered biomarkers that may be used to monitor
disease.
What This Study Adds to the Field
High-throughput mass spectrometry identifies key bio-
markers in sputum, allowing quantitative measurement
with immunoassay, and potential development of new
clinically applicable tests of inflammation in lung disease.
(Received in original form March 13, 2007; accepted in final form June 17, 2008)
G.M. and A.C.B. were funded through the U.K. Cystic Fibrosis Gene Therapy
Consortium. R.D.G. was supported by the Medical Research Council (program
grant G9313618). D.N. was supported by an unrestricted Investigator Grant
from GlaxoSmithKline.
Correspondence and requests for reprints should be addressed to Professor
Andrew P. Greening, M.D., F.R.C.P., Respiratory Unit Offices, 1st Floor, Anne
Ferguson Building, Western General Hospital, Crewe Road, South Edinburgh EH4
2XU, UK. E-mail: a.greening@ed.ac.uk
This article has an online supplement, which is accessible from this issue’s table of
contents at www.atsjournals.org
Am J Respir Crit Care Med Vol 178. pp 444–452, 2008
Originally Published in Press as DOI: 10.1164/rccm.200703-409OC on June 19, 2008
Internet address: www.atsjournals.org
to identify individual potential biomarkers for further charac-
terization may be a more valid and robust approach. SELDI-
TOF has been applied to a small number of patients with
chronic obstructive pulmonary disease (COPD) demonstrating
a protein profile in BAL (23), and in pulmonary sarcoidosis
(24). SELDI-TOF has been used to demonstrate protein
expression in BAL in CF (25, 26). There is as yet a lack of
published data using SELDI-TOF to profile sputum, although
complementary proteomic approaches of two-dimensional elec-
trophoresis (27), shotgun protein sequencing (28), and affinity
immunoproteomics (29) have been applied to sputum in an
effort to discover new biomarkers.
We applied SELDI-TOF to induced sputum from patients
with inflammatory (asthma, COPD) and suppurative (CF,
bronchiectasis) airway diseases to determine whether a high-
throughput proteomics screening method can reveal differential
protein expression between disease groups and therefore can-
didate biomarkers, which may then be developed into point
assays of inflammation with potential application in the clinic.
This work was driven by the need to develop biomarkers to
monitor suppurative lung disease, in particular CF.
METHODS
Subjects and Selection
The Lothian Ethics Committee (Edinburgh, UK) granted ethical
approval and all participants gave written consent. Sputum was
obtained from 28 patients with CF, 19 with bronchiectasis, 24 with
asthma, 24 with COPD, and 20 healthy control subjects. All patients
were clinically stable and recruited from the outpatient clinic of
a respiratory medicine unit. All subjects were recruited from specialist
respiratory clinics at a major teaching hospital where they were
attending with a diagnosis of their respective illness. In the absence
of preexisting data on intersubject variability, formal statistical power-
ing was not possible, but we approached this problem by recruiting
similar numbers of subjects to previous biomarker studies. The patient
groups represented respiratory diseases with clinical features that both
complement and contrast with each other.
Longitudinal Data
To determine the usefulness of discovered markers in the assessment of
lung disease during a changing level of inflammation, longitudinal
samples were collected from 12 patients with CF during an infective
exacerbation. Samples were collected at onset and completion of
intravenous antibiotic therapy (duration, 14–21 d). The biomarkers
were assessed both by SELDI-TOF and by ELISA.
Induced Sputum
Sputum induction was performed as previously described (30). Subjects
inhaled nebulized hypertonic saline at concentrations of 3, 4, and 5%.
Sputum was processed within 2 hours of collection (31). Sputum plugs
were selected and processed with 4 3 weight/volume of 0.1%
dithiothreitol after which 4 3 weight/volume of phosphate-buffered
saline was added. Samples were filtered through 48-mm mesh and
centrifuged to remove the cells. Supernatants were stored at 2808C
until further analysis. Cytospins were stained with May-Grunwald-
Giemsa for differential cell counting.
SELDI-TOF MS
Three different chromatographic chip surfaces were used to cover
a wide range of protein characteristics: a weak cation exchange at pH 4
(CM10), an anion exchange at pH 10 (Q10), and an immobilized metal
affinity surface activated with nickel (IMAC nickel [IMACNi]). In-
duced sputum samples were adjusted to contain 1 mg/ml protein at
a concentration of 0.1% dithiothreitol. Ten microliters of sample were
added to CM10 and Q10 surfaces in a bioprocessor unit (Ciphergen,
Freemont, CA) and 1 ml of sample was added to the preactivated
IMACNi surface for on-spot incubation (more reproducible for IMACNi
surfaces). All chips were treated with sinapinic acid (SPA) matrix (2 3
0.8 ml/spot) and allowed to air dry. Samples were analyzed on the
Protein Biology System 2 SELDI-TOF mass spectrometer (Cipher-
gen). Chips were read with a laser intensity of 205 with the deflector set
at 4,000 D and a focus mass of 7,500 D. Profiles were then exported to
Ciphergen Express (Ciphergen) for clustering and data analysis. Intra-
and interassay coefficients of variation were assessed with the CM10
surface as outlined in the online supplement.
Data Analysis
Data were normalized to total ion current to take into account any spot
to spot variability in chip surface binding. Data with high normalization
coefficients were identified and individual spectra examined. Poor-
quality spectra or absent signal were excluded from further analysis.
Protein peaks were automatically clustered to identify biomarkers of
similar molecular weight. Mann-Whitney rank testing was performed
to demonstrate statistical differences in clusters between disease
groups. Values of P , 0.01 were taken to be significant. For longitu-
dinal data, paired t test analysis was performed using Prism 4 software
(GraphPad, San Diego, CA). For a further description of methods,
please refer to the online supplement.
Protein Identification
Highly significant peaks (P , 0.0001), assessed on relative abundance
and quality of original spectral data, were selected for protein iden-
tification. Pooled sputum was used. Samples were applied to 18%
trisene/glycine acrylimide gel for electrophoresis. Bands of appropriate
molecular weight were excised and destained and the protein eluted.
The eluate was digested with proteomics grade trypsin (Sigma,
Gillingham, UK), applied to a normal-phase chromatography chip
surface and analyzed with SELDI-TOF MS or MALDI (matrix-
assisted laser desorption/ionization)-TOF MS using a Voyager DE
STR mass spectrometer (Applied Biosystems, Foster City, CA). The
resultant mass fingerprint was used to identify the parent protein
through reference to protein identification databases (MS-Fit; Univer-
sity of California, San Francisco, San Francisco, CA). Proteins were
identified based on molecular weight search (MOWSE) score and
cross-checked with online MASCOT (http://www.matrixscience.com),
which allows a probability-based MOWSE score. Protein identification
was only accepted when P values were less than 0.05. Tandem MS/MS
analysis was performed to confirm identification of proteins using a
Q-star tandem MS instrument (Applied Biosystems) with SELDI
chip interface (Ciphergen). This approach provided additional pro-
tein identification based on amino acid sequence from the MS/MS
analysis.
Commercial antibodies, when available, were used for protein con-
firmation by Western blotting. For calgranulins A and B, we were also
able to use an in-house quantitative immunoassay measuring calprotectin
(calgranulin A/B complex). An in-house double antibody sandwich ELISA
(antibodies and calprotectin standard courtesy of E. Sundrehagen,
M.D.) was developed for use in the 12 patients with CF monitored
longitudinally, and results compared with data from SELDI-TOF.
RESULTS
Demographics
Patient demographics are given in Table 1. Of the patients with
CF, 18 were chronically infected with Pseudomonas aeruginosa.
Reproducibility of SELDI-TOF Assay in Sputum
This was assessed as described in the online supplement. The
intraassay coefficient of variation ranged from 11.5 to 44% with
an average coefficient of variation (CV) of 22.4%. Interassay
variation demonstrated a CV ranging from 6 to 43%, with an
average CV of 16.2%.
Protein Profiles Generated by SELDI-TOF
An example of generated data is demonstrated in Figures 1 and 2.
Cluster analyses determined a large number of peaks present in
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relative proportions that differentiated between disease groups
and healthy controls (Table 2). Three chip surfaces yielded
a total of 621 clustered protein peaks, 105 of those significantly
different at P , 0.01 and 56 at P , 0.001 for asthma versus
healthy controls. For COPD compared with healthy controls,
the respective figures were 625 protein peaks, with 113 signif-
icant at P , 0.01 and 50 at P , 0.001 for three surfaces. For
bronchiectasis versus healthy controls, the respective figures
were 671 protein peaks, with 377 significant at P , 0.01 and 314
at P , 0.001 for three surfaces. For the CF group, the respective
figures were 660 protein peaks, with 381 significant at P , 0.01
and 315 at P , 0.001 for three surfaces (Table 2; for full
summary, see Table E1 in the online supplement).
Although all four groups of patients yielded a substantial
number of differential proteins compared with healthy control
subjects, there were much closer similarities between the two
obstructive airway diseases and between the two suppurative
airway diseases. For asthma and COPD, only 16 proteins, on the
three chip surfaces, were different at P , 0.01, and one protein
was different at P , 0.001 (Table 2; Table E1). This latter
protein, molecular weight (MW) 29 kD, was seen on the
IMACNi surface (Figure 3A) but had low signal intensity. This
marker has not yet been identified. CF and bronchiectasis
demonstrated relatively similar biomarker profiles compared
with each other, albeit the abundance of protein in the CF
group was greater. Fifty-eight proteins differentiated the groups
at P, 0.01 and 9 proteins differentiated the groups at P, 0.001
(Table 2; Table E1) over the three surfaces. Five of these nine
proteins were observed on the IMACNi surface, two on CM10
and two on Q10. The marker that showed the greatest separa-
tion between the disease groups and had the highest signal
intensity had an MW of 12.246 kD (Figure 3B). We have not
identified this protein.
Figure 1. This figure demonstrates spectra from individual subjects on the immobilized metal affinity chromatography (IMAC) nickel surface in the
mass range of 5 to 15 kD. Even in this mass range, there is an abundance of peptide peaks, and noticeable differences are observed between groups.
B’iectasis 5 bronchiectasis; CF 5 cystic fibrosis; COPD 5 chronic obstructive pulmonary disease.
TABLE 1. DEMOGRAPHIC, LUNG FUNCTION, AND SPUTUM
NEUTROPHIL DATA OF THE PATIENTS STUDIED
Group Age (yr) Sex FEV1 (% pred) Sputum Neutrophil (%)
Asthma 47.8 (2.9) 15 F/8 M 82.3 (4.4) 50.6 (5.0)
COPD 65.2 (1.2) 10 F/14 M 57.7 (4.1) 79.1 (2.7)
Bronchiectasis 61.8 (3.5) 15 F/3 M 71.7 (11.6) 83.2 (5.6)
CF 28.8 (1.7) 8 F/19 M 59.2 (3.9) 91.6 (2.0)
Control 36.4 (2.1) 11 F/9 M 101.4 (3.1) 54.2 (5.3)
Definition of abbreviations: CF 5 cystic fibrosis; COPD 5 chronic obstructive
pulmonary disease; F 5 females; M 5 males.
Values are mean (SEM).
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The top 20 protein peaks that showed the most statistically
significant differences between individual disease groups and
healthy controls are shown in Table E2, indicating their mo-
lecular weight and the chip surface on which they were iden-
tified. There are common peaks found in asthma and COPD,
and CF and bronchiectasis.
Biomarker Identification
The proteins we have formally identified from the induced
sputum samples are calgranulin A, calgranulin B, calgranulin C,
Clara cell secretory protein (CCSP, CC16, CCSP10, uteroglo-
bin), lysosyme c, proline rich salivary peptide, cystatin s, and
hemoglobin a (Table 3).
Calgranulins A, B, and C were highly abundant in CF and
bronchiectasis, but were also seen in the other disease groups.
These proteins are represented by mass spectral peaks at 10.831
kD, 12.700 kD, and 10.100 kD, respectively. These peaks were
preferentially expressed on the IMACNi surface but were also
bound to the weak cation exchange surface. Some binding of
calgranulin A was also demonstrated on the anion exchange
surface. A separate form of calgranulin A with a lower molec-
ular weight (10.574 kD) was seen in the CF and bronchiectasis
groups. This was identified by mass fingerprinting of both
molecular weights after purification on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (data not shown). The relative
expression of calgranulin A across all groups is shown in Figure
4A and the relative expression of the smaller form of calgra-
nulin A in Figure 4B. The presence of calgranulin A was
confirmed with Western blotting in pooled sputum samples
from all disease and control groups (Figure 4C).
In contrast to the calgranulins, CCSP was in lower abun-
dance in all disease groups compared with controls, but to the
greatest extent in CF and bronchiectasis. This had a mass
spectral peak of 7.900 kD on the CM10 surface. The relative
expression of CCSP across all groups is shown on Figure 5.
CCSP was confirmed on Western blot (data not shown).
Correlation of Biomarkers with FEV1 and Sputum Cytology
In the CF group, the most abundant biomarker, calgranulin A,
showed a weak inverse correlation with FEV1% predicted,
which failed to reach statistical significance (Spearman r 5
0.63, P 5 0.08). There was no correlation of calgranulin A with
the percentage of sputum neutrophils (data not shown).
Figure 2. This figure demonstrates spectra
from an individual with cystic fibrosis (CF)
on the CM10 (cationic exchange) surface
shown at different magnifications demon-
strating the abundance of peaks in an
individual sample. (A) demonstrates the
entire spectrum (3,000–50,000 D); each
label (most of which cannot be discerned
individually at this magnification) repre-
sents a peak with signal-to-noise ratio of
more than 3. (B) demonstrates some mag-
nification to cover the spectrum from
5,000 to 20,000 D; again, most of the
individual labels cannot be seen clearly at
this magnification. (C ) demonstrates mag-
nified spectrum from 6,500 to 7,000 D,
and at this level the individual peaks can be
easily discerned.
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Longitudinal Assessment of Identified Biomarker and
Application of Specific ELISA
There were decreases in the levels of both calgranulin A and B,
as assessed by SELDI-TOF, during treatment of an exacerba-
tion of CF (Figures 6A and 6B; P , 0.01). Calprotectin
(heterodimer of calgranulins A and B), measured by ELISA,
similarly showed significant reduction (Figure 6C).
DISCUSSION
The use of SELDI-TOF MS has allowed us to generate sputum
protein profiles of several diseases. We have shown there are
substantial numbers of potential protein biomarkers that dif-
ferentiate patients with inflammatory airway diseases from
healthy subjects. We have proceeded to identify several of
these candidate biomarkers and, using the example of calgra-
nulins A and B, have demonstrated clinical relevance with
longitudinal evaluation during altered disease activity. We have
demonstrated that, having identified a biomarker by primary
screening rather than empirical preselection, a standard assay,
ELISA, can then be applied to the same clinical samples and
deliver quantitative measures of the biomarker. Thus, screening
with high-technology SELDI-TOF proteomics can be converted
into clinically applicable measures.
Because this is the first study of its kind to investigate the
proteomics of induced sputum using SELDI-TOF, we sought to
determine the reproducibility of this assay. The average intra-
assay CV was 22.41% and average interassay CV was 16.25%.
This compares well to published data for serum (intraassay CV
of 15.6%, interassay variation of 24.4% [19], urine (intraassay
CV, 8–30%) (32), and saliva (intraassay CV, 18%, and inter-
assay CV, 31%) (33).
Previous studies have demonstrated the utility of SELDI-TOF
in the diagnosis of illnesses in a range of body fluids. We used the
fluid phase of sputum as a noninvasive means of assessing the
airways. Although previous work has suggested a correlation of
induced sputum with bronchial washings but not BAL (34), and
therefore suggests that it reflects the pathophysiology of more
central airways, induced sputum has been demonstrated useful in
inflammatory respiratory diseases (11, 12, 35–46). Therefore, we
would conclude that the proteomic assessment of induced sputum
is a valid means of assessing airway disease.
As described previously, SELDI-TOF technology has been
used as a technique in a number of inflammatory and neoplastic
diseases, mainly using serum as a sampling medium. It was
suggested as a diagnostic platform using bioinformatic algo-
rithms to separate subjects with ovarian cancer from healthy
control subjects (15). This initial approach, however, was widely
criticized in the literature because the results were not re-
producible when the same data sets were examined by in-
dependent investigators (21). Baggerly and colleagues (21) drew
particular notice to the impact of different modes of data
preparation after acquisition, such as baseline subtraction in
some groups of data and not in others. They also suggested that
inaccuracies in sample collection protocol and mass calibration
could lead to misinformed results in these sorts of experiments.
To ensure uniformity in this study, all data in our analysis
underwent the same steps of preparation before analysis. We
also ensured that all sample preparation was uniform as out-
lined in METHODS and below. Mass calibration was performed
before each experiment using protein and peptide standards
(Ciphergen All in One protein and peptide standards; Cipher-
gen). Furthermore, the widely criticized Petricoin study also
used mass spectral data at less than 1,000 D, a mass range at
TABLE 3. PROTEIN IDENTIFICATIONS CONFIRMED FROM PRESENT STUDY
Protein
Molecular
Weight (D)
Accession
Number
Corresponding
SELDI Peak (D)
Confirmed
by PMF
Confirmed
by MS/MS
Confirmed
By Antibody
Direction of
Change in Suppuration
Calgranulin A 10,834 P05109 10,834, 10,596 Yes Yes Yes Increased
Calgranulin B 12,960 P06702 12,960, 13,200 Yes Yes Yes Increased
Calgranulin C 10,100 P80511 10,100 Yes Yes No Increased
Clara cell secretory protein 7,900 P11684 7,900 Yes Yes Yes Decreased
Proline rich salivary peptide 8,188 P02814 8,119 No Yes No Decreased
Lysosyme C precursor 16,537 P61626 14,600 Yes Yes No No Change
Cystatin s 16,204 P01036 16,079 No Yes No No Change
hemoglobin alpha 15,117 P69905 15,080 No Yes No No Change
Definition of abbreviations: PMF 5 peptide mass fingerprinting; SELDI 5 surface-enhanced laser desorption/ionization.
Proteins were identified by trypsin digest and PMF and well as tandemMS/MS. When available, antibodies were used to confirm protein identification by Western blot.
Molecular weight refers to the theoretical molecular weight of each protein as derived from sequence. Corresponding SELDI peak refers to the protein peak seen on
SELDI analysis of sputum fluid phase (differences in molecular weight may represent post-translational modifications).
TABLE 2. THE TOTAL NUMBER OF PEAKS DETECTED BY SELDI-TOF
IMAC Nickel Weak Cation Exchange (CM10) Anion Exchange (Q10)
Asthma vs. control 4 (n 5 22 vs. 20) 16 (n 5 20 vs. 19) 36 (n 5 16 vs. 18)
COPD vs. control 11 (n 5 23 vs. 20) 13 (n 5 22 vs. 19) 26 (n 5 21 vs. 18)
CF vs. control 108 (n 5 28 vs. 19) 111 (n 5 22 vs. 19) 96 (n 5 22 vs. 19)
Bronchiectasis vs. control 112 (n 5 19 vs. 20) 103 (n 5 17 vs. 19) 99 (n 5 18 vs. 19)
CF vs. bronchiectasis 19 (n 5 28 vs.19) 18 (n 5 28 vs. 17) 21 (n 5 22 vs. 19)
Asthma vs. COPD 10 (n 5 23 vs. 22) 5 (n 5 21 vs. 20) 1 (n 5 21 vs. 25)
Definition of abbreviations: CF5 cystic fibrosis; COPD 5 chronic obstructive pulmonary disease; SELDI-TOF 5 surface-enhanced
laser desorption/ionization time-of-flight.
Significantly different (P , 0.001) for disease versus control are shown. The two suppurative airway diseases, CF and
bronchiectasis, and the two inflammatory airway diseases, asthma and COPD, were also compared in terms of numbers of
differentiating proteins (P , 0.01). Proteins could be increased or decreased in their abundance. Spectra that failed normalization
were excluded from analysis (see text). n 5 number of normalized spectra used in each analysis, as per order in table legend. The
spectra failing to normalize were not the same for each analysis. The data are displayed for each of the three chip surfaces that
were used in the study.
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which the discrimination of genuine protein peaks from back-
ground noise may be difficult. Our approach of excluding data
from below 4,000 D from analysis further strengthens the
findings of this study. Other studies using SELDI-TOF as
a diagnostic platform in infectious diseases using more robust
sample collection and data preparation algorithms have proved
more promising (19, 20). However, in this study, we used
SELDI-TOF as a high-throughput screening platform for bio-
marker discovery rather than as a primary diagnostic assay.
Although, on initial observation, our data demonstrate a large
number of differentiating peaks when we look at the combined
data set, the actual clinical significance of this observation is less
clear and should be interpreted with caution.
Previous work by our group suggested an optimum mass
range for respiratory biomarker discovery with this platform to
be 3 to 20 kD (25). This may lead to biomarkers of a higher
mass being ignored. Other proteomics methods, such as two-
dimensional gel electrophoresis and immunocapture, may be
better in assessing larger molecular weight proteins, and has
been applied to CF (27, 29).
The largest numbers of differentiating proteins between
disease and control were found in CF and bronchiectasis. This
may suggest greater numbers of inflammatory and disease-
Figure 3. (A) The protein that gave the statistically greatest differen-
tiation between asthma and chronic obstructive pulmonary disease
(COPD) (P , 0.001) had a MW of 29 kD, and was detected on the
IMAC nickel (IMACNi) surface. The individual data and the median bars
are shown. The data are for 22 patients with asthma and 23 patients
with COPD (see explanation in footnote to Table 2). Other disease
groups are demonstrated for comparison. (B) The protein that gave the
statistically greatest differentiation between cystic fibrosis (CF) and
bronchiectasis (B’iectasis) (P , 0.001) had an MW of 12.246 kD, and
was detected on the IMACNi surface. The individual data and the
median bars are shown. The data are for 28 patients with CF and 19
patients with bronchiectasis (see explanation in footnote to Table 2).
Other disease groups are demonstrated for comparison.
Figure 4. Calgranulin A in all disease groups: (A) shows the relative
expression, on surface-enhanced laser desorption/ionization time-of-
flight (SELDI-TOF), of the 10,831-D protein, which was elevated (P ,
0.001) in all disease groups versus control; (B) shows the expression of
the 10,576-D form of calgranulin A, which was specifically elevated in
patients with cystic fibrosis (CF) and bronchiectasis (B’iectasis) (P ,
0.001 vs. all other groups) (the data in A and B were obtained using the
IMAC Nickel surface); (C) is a Western blot of calgranulin A. The blot
represents the overall abundance of calgranulin A from both 10,834-
and 10,576-D forms in the sample groups (lanes are labeled as Bl 5
blank, A 5 asthma; Br 5 bronchiectasis; CF 5 cystic fibrosis; Con 5
control; CO 5 COPD). Note the strong staining for CF and bronchi-
ectasis groups and very weak staining in asthma. (D) demonstrates the
effect of bacterial colonization on the signal intensity of the 10,576-D
form of calgranulin A; the majority of patients were colonized with
Pseudomonas aeruginosa (shown in the first column labeled ‘‘Pseudo-
monas’’); other organisms included Staphylococcus aureus, Haemophi-
lus, Stenotrophomonas, and Burkholderia (labeled ‘‘Other’’).
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related proteins in these groups or, alternatively, samples obtained
from these groups had greater abundance of protein overall.
Sputum samples obtained from subjects with CF and bronchiec-
tatic subjects were of greater volume and better quality sub-
jectively. However, selected mucus plugs were used for analysis
and processed with equal ratios of buffer as previously described
(46). Moreover, to ensure samples were comparable, superna-
tants were adjusted to a total protein concentration of 1 mg/ml
before applying to chip surfaces. Also, mass spectral data were
normalized to total ion current before data analysis, thus
minimizing effects of possible variation in protein binding to
chip surfaces. After normalization, samples were excluded be-
cause they had absent or very poor signals. We would therefore
suggest that the differences expressed between groups represent
real differences in protein expression rather than confounding
due to issues of sample quality and abundance.
Our data revealed large numbers of potential biomarkers. The
preset parameters we created may have limited the possible
number. A lower limit cutoff of 4 kD may have been too harsh.
Indeed, our spectra showed the human a defensins in all groups,
but these were excluded from analysis because their average mass
was less than 4 kD. Alternatively, we may have overestimated
true numbers of differentiating markers because some proteins
were detected on more than one chip surface. Also, a proportion
of some proteins may be doubly protonated. Because the ‘‘time
of flight’’ is related to both MW and charge, such proteins will
appear ‘‘twice,’’ once with half the MW of the original protein.
Furthermore, different peaks may represent cleavage products of
the same (higher molecular weight) proteins and this may in part
explain the high numbers of potential differentiating peaks we
recorded, particularly when comparing our CF and bronchiectasis
groups with control subjects.
Despite finding a large number of peaks differentiating CF
and bronchiectasis from controls, we were surprised not to have
identified any of these as known biomarkers of inflammation,
such as IL-8 or neutrophil elastase. In our study, SELDI-TOF
was most efficient at demonstrating peaks in the 5–20-kD range
and this may in part explain these findings as the predicted
molecular weights of neutrophil elastase is 29.5 kD (47).
Furthermore, the chip surface chemistry and binding conditions
may simply not have favored preferential selection of IL-8.
Despite the limitations in this technique, we found large
numbers of potential biomarkers from which we have so far
identified a modest number, although further identification of
other peaks is ongoing. We used one of these biomarkers,
calprotectin (calgranulin A and B), to show that it was possible
to monitor disease activity and to apply an ELISA to the same
clinical samples, obtaining the same results as with MS.
In all disease groups, we identified calgranulin A at higher
levels than in control subjects. This S100 protein is produced by
neutrophils, macrophages, and epithelial cells. In the CF and
bronchiectasis groups, a protein at 10.574 kD was also identified
as calgranulin A. Theoretical removal of glutamic acid and
lysine from the N terminus of calgranulin A would result in
an identical mass shift from 10.831 to 10.574 kD. Calgranulin
10.574 may therefore be the product of specific cleavage or post-
translational modification in CF and bronchiectasis. Whether
this finding may be of functional significance is as yet unclear.
Calgranulins A and B have also been described recently in
BAL fluid from subjects with CF (25, 26); a similar finding of
a separate peak representing calgranulin A at a lower molecu-
lar weight was also described in BAL fluid by McMorran and
colleagues (26).
Calgranulin has previously been described in the sera of
subjects who were homo- and heterozygous for CF mutations
and was referred to as CF antigen (48). Calgranulin A may
Figure 5. Clara cell secretory protein, molecular weight (MW) 7.9 kD,
was in lower abundance for all disease groups compared with controls,
but to the greatest extent in cystic fibrosis (CF) and bronchiectasis
(B’ectasis). These data were obtained using the cation exchange
(CM10) surface. The individual data and the median bars are shown.
The data are for 20 patients with asthma, 17 with bronchiectasis, 22
with CF, 22 patients with chronic obstructive pulmonary disease
(COPD), and 19 control subjects (see explanation in footnote to Table 2).
Figure 6. The results for calgranulins A and B/calprotectin for 12
patients with cystic fibrosis are shown at the onset of an infective
exacerbation and at the completion of antibiotic therapy, when there
was a decrease (P , 0.01) of the proteins measured. (A) shows data for
calgranulin A; (B) shows data for calgranulin B; (C) shows data for
calprotectin measured by ELISA.
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provide a robust and sensitive marker of airway inflammation in
CF. The likely source of calgranulin A is from neutrophils in the
airway, although in this study we failed to demonstrate any
significant correlation between neutrophil % in sputum and
calgranulin A as measured by SELDI-TOF. This may in part be
explained by the finding that the majority of the patients with
CF had a profound neutrophilia in sputum in excess of 95%,
regardless of other clinical details. Furthermore, there was
a weak relationship between decreasing FEV1 and higher levels
of calgranulin A, implying that calgranulin A may be a marker
of disease severity in CF. We replicated our SELDI-TOF results
using an ELISA to calprotectin, the heterodimer of calgranulins
A and B. Thus, a more practical assay can be applied to induced
sputum and yield the same clinical information. Calprotectin
has previously been recognized as a marker in other inflamma-
tory disorders, including inflammatory bowel disease and ar-
thritis (49–51). Calgranulin C, another S100 protein, was also
identified in our samples. This is in keeping with previous work
demonstrating its presence in sputum and its potential useful-
ness as a biomarker in serum for CF (52).
A second abundant protein identified showed opposite
effects to calgranulin A. CCSP was reduced in all disease
groups compared with controls. CCSP is an antiinflammatory
protein mainly expressed in the epithelial cells of the airways.
Low serum levels have been reported in patients with asthma
(53), and low nasal lavage levels in patients with allergic rhinitis
(54). CCSP has a number of possible activities, including
inhibition of phospholipase A2, chelation of calcium, and
down-regulation of IFN-g, IL-1, and tumor necrosis factor-a.
Our findings are consistent with these previous studies, and
raise the possibility that resolution of inflammatory processes
might be monitored by rising levels of CCSP.
In conclusion, we have demonstrated the utility of SELDI-
TOF MS as a tool for biomarker discovery in induced sputum.
We have positively identified proteins of biological significance
in the fluid phase of sputum. These proteins may form the basis
of clinical point assays to assess the presence and activity of
inflammation in a variety of lung diseases, with a particular
emphasis being placed on disease monitoring.
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